儿童风湿病患者SARS-CoV-2血清阳性率及临床结局
本研究纳入纽约三级儿童风湿科262例接受免疫抑制治疗的儿童风湿病患者,2020年5月至11月行SARS-CoV-2 IgG检测,35例(13%)阳性,其中17例有COVID-19症状,症状者均为轻症,无重症、危重症或住院。
要点
- 儿童风湿病患者SARS-CoV-2 IgG阳性率为13%(35/262)。
- IgG阳性者中49%(17/35)有COVID-19症状,均为轻症。
- 无IgG或PCR阳性者发展为重症、危重症或需住院。
核心结论
- 免疫抑制儿童风湿病患者中大多数SARS-CoV-2 IgG阳性者无症状,有症状者均为轻症,重症或危重症风险极小。
研究设计与样本
- 研究纳入18岁前诊断风湿病且接受至少一种免疫抑制药物治疗至少3个月的患儿,来自纽约三级儿童风湿科,2020年5月至11月行常规SARS-CoV-2 IgG检测,筛查571例,入组262例。
主要发现
- 262例中186例女性,35例(13%)SARS-CoV-2 IgG阳性,其中17例(49%)有提示COVID-19的症状。
- 17例接受SARS-CoV-2 PCR检测者中11例(65%)PCR阳性,其中7例同时IgG阳性。
- IgG和/或PCR阳性者最常见症状为发热、疲劳和咳嗽。
- 无SARS-CoV-2 IgG或PCR阳性者发展为重症或危重症COVID-19或需要住院。
临床怎么用
- 本研究提示免疫抑制儿童风湿病患者感染SARS-CoV-2后重症风险低,有症状者多为轻症,可据此评估临床风险。
局限性
- 大多数SARS-CoV-2 IgG阳性者未进行PCR检测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Immunosuppressed paediatric patients with rheumatic disease (RD) may be at risk for severe or critical disease related to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Data remain scarce on coronavirus disease 2019 (COVID-19) outcomes in paediatric RD patients. The aim of this study was to determine the seroprevalence of SARS-CoV-2 IgG and to describe COVID-19 outcomes in immunosuppressed paediatric RD patients. METHODS: Patients diagnosed with RD before age 18 years and treated with at least one immunosuppressive medication for at least 3 months were enrolled from a tertiary paediatric rheumatology practice in New York and also underwent routine SARS-CoV-2 IgG testing from May to November 2020. A total of 571 patients were screened and 262 were enrolled. SARS-CoV-2 IgG-positive subjects were assessed for symptoms of COVID-19 infection. SARS-CoV-2 PCR results were recorded where available. Demographic, diagnostic, medication and outcome data were collected. RESULTS: Of 262 subjects (186 female), 35 (13%) were SARS-CoV-2 IgG positive; 17 (49%) had symptoms suggestive of COVID-19. Of the 17 patients who had SARS-CoV-2 PCR testing, 11 (65%) were PCR positive, 7 of whom were IgG positive. Most SARS-CoV-2 IgG-positive subjects were not PCR tested. The most common symptoms in IgG- and/or PCR-positive subjects were fever, fatigue and cough. No SARS-CoV-2 IgG- or PCR-positive subject developed severe or critical COVID-19 or required hospitalization. CONCLUSIONS: This is the first report of clinical outcomes of SARS-CoV-2 infection and seroprevalence of SARS-CoV-2 IgG in a large cohort of paediatric RD patients. Most SARS-CoV-2 IgG-positive subjects had no symptoms of COVID-19 infection. Symptomatic subjects all had mild COVID-19 symptoms, suggesting that the risk of severe or critical COVID-19 in immunosuppressed paediatric RD patients is minimal.
引用
- Walters HM, Mian Z, Thomas L, et al. Seroprevalence and clinical outcomes of SARS-CoV-2 in paediatric patients with rheumatic disease. Rheumatology (Oxford). 2022. PMID: 34599820. doi:10.1093/rheumatology/keab730
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。